Publications by the researcher in collaboration with Ana María García Osta (16)

2019

  1. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class i Histone Deacetylase Selective Inhibitors

    ACS Chemical Neuroscience, Vol. 10, Núm. 3, pp. 1765-1782

  2. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles

    ACS Chemical Neuroscience, Vol. 10, Núm. 9, pp. 4076-4101

  3. Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat Alzheimer's disease

    Frontiers in Aging Neuroscience, Vol. 11, Núm. JUN

2018

  1. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 150, pp. 506-524

  2. Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 742-750

2017

  1. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice

    Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539

  2. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease

    ACS Chemical Neuroscience, Vol. 8, Núm. 3, pp. 638-661

2016

  1. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 59, Núm. 19, pp. 8967-9004

  2. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

2015

  1. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

    Clinical Epigenetics, Vol. 7, Núm. 1

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

2014

  1. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

2013

  1. Epigenetic drugs in Alzheimer's disease

    Biomolecular Concepts, Vol. 4, Núm. 5, pp. 443-445

  2. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD

    Neuropharmacology, Vol. 64, pp. 114-123

2012

  1. Phosphodiesterases as therapeutic targets for Alzheimer's disease

    ACS Chemical Neuroscience, Vol. 3, Núm. 11, pp. 832-844

2011

  1. Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease

    Current Medicinal Chemistry, Vol. 18, Núm. 36, pp. 5545-5553